Source: Walker R.F., Clinical Interventions in Aging, 2007, PMC2699646
Article Objective
To discuss the potential of Sermorelin as a more physiological and safer alternative to recombinant human growth hormone (rhGH) in adults with GH deficiency or age-related decline in its secretion.
Background Information
Traditional rhGH therapy is effective in counteracting somatic aging but carries several risks:
- Incorrect dosing can cause serious side effects.
- Exogenous GH creates non-physiological ("square-wave") peaks that are not feedback-controlled.
- The legal framework limits the use of rhGH to specific clinical indications (AIDS or proven GHD).
Sermorelin (GHRH 1–29 NH2-acetate) is an analog of the natural growth hormone-releasing hormone (GHRH), whose levels decline with age. By binding to receptors in the pituitary gland, it activates endogenous GH release, mimicking physiological pulsation.
Key Advantages over rhGH
- Physiological control: Effects are regulated by somatostatin, which prevents overdose.
- Pulsatile secretion: GH release is episodic, not a constant peak, as with rhGH.
- No tachyphylaxis: Secretion remains sensitive to stimuli due to a natural release rhythm.
- Maintains pituitary function: Stimulates GH mRNA transcription and increases hormonal reserve.
- Slows aging of the endocrine axis: Helps preserve normal physiology with age.
Legal and Clinical Status
Unlike rhGH, Sermorelin has no federal restrictions on prescription in adults, allowing clinicians to use it off-label within research protocols to assess its efficacy and safety.
Conclusion
- Sermorelin offers a more physiological approach to GHRT in adults.
- Reduces the risk of side effects and maintains the natural regulation of the GH/IGF-1 axis.
- Can be used as a safe and legal alternative for maintaining hormonal balance in aging.
